CONMED Boosts 2026 Revenue Guidance as Q1 Profits Surge

CONMED Corporation (CNMD) announced first-quarter financial results characterized by a sharp rise in net income, overcoming a marginal decline in total sales. The company's bottom line more than doubled year-over-year, reflecting improved operational margins and strategic shifts in its product portfolio. Net sales for the quarter reached $317.0 million, a 1.3% decrease from the $321.3 million reported in the prior year. This decline was primarily attributed to a $15.5 million reduction resulting from the company's strategic exit from specific gastroenterology product lines. Regional performance showed a divergence, with domestic revenue falling 5.8% while international markets grew by 4.7%. Despite the sales dip, net income climbed to $13.8 million, or $0.45 per share, compared to $6.0 million, or $0.19 per share, in the same period last year. Adjusted earnings per share were $0.89, slightly trailing the previous year's $0.95. Looking forward, CONMED has increased its full-year 2026 organic revenue growth outlook to between 5.0% and 6.5% in constant currency. The company now expects reported revenue to fall between $1.35 billion and $1.375 billion, a slight increase from previous guidance. Adjusted EPS guidance remains steady at $4.30 to $4.45. CEO Patrick J. Beyer noted that the company is prioritizing investments in higher-growth, higher-margin areas, specifically minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair, to maintain the momentum established in 2025.